Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · IEX Real-Time Price · USD
0.121
-0.021 (-14.64%)
At close: Sep 29, 2023, 4:00 PM
0.123
+0.003 (2.24%)
After-hours: Sep 29, 2023, 7:59 PM EDT
-14.64%
Market Cap 7.59M
Revenue (ttm) 16.96M
Net Income (ttm) -24.77M
Shares Out 62.87M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 73,969,741
Open 0.141
Previous Close 0.141
Day's Range 0.120 - 0.147
52-Week Range 0.081 - 7.000
Beta 1.26
Analysts Hold
Price Target 1.88 (+1,457.58%)
Earnings Date Nov 6, 2023

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also devel... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2015
Employees 20
Stock Exchange NASDAQ
Ticker Symbol AVTX
Full Company Profile

Financial Performance

In 2022, AVTX's revenue was $18.05 million, an increase of 234.40% compared to the previous year's $5.40 million. Losses were -$41.66 million, -50.63% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AVTX stock is "Hold." The 12-month stock price forecast is $1.88, which is an increase of 1,457.58% from the latest price.

Price Target
$1.88
(1,457.58% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed t...

5 days ago - GlobeNewsWire

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Avalo Therapeutics (NASDAQ: AVTX) stock price has become unloved and unwanted in the past few months. It has become a penny stock as it is trading at $0.1630, down from its all-time high of $91.65.

5 days ago - Invezz

3 penny stocks to buy under $1 in September

Due to its low price, penny stocks may seem like a good place to invest your money. But they come with high risk.

Other symbols: AFMDZVSA
17 days ago - Finbold

Avalo Enters into Agreement to Divest AVTX-800 Series

WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Thera...

19 days ago - GlobeNewsWire

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, w...

25 days ago - GlobeNewsWire

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2023.

2 months ago - GlobeNewsWire

Avalo to Participate in SVB Securities Therapeutics Forum

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, wi...

3 months ago - GlobeNewsWire

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

WAYNE, Pa. and ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced topline results from the Phase 2 randomized, double-blind, placebo-controlled ...

3 months ago - GlobeNewsWire

Avalo to Present at the Jefferies Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, wi...

4 months ago - GlobeNewsWire

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company's Scientific ...

4 months ago - GlobeNewsWire

Avalo to Present at ATS 2023 Respiratory Innovation Summit

WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, wil...

4 months ago - GlobeNewsWire

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, wil...

5 months ago - GlobeNewsWire

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2023.

5 months ago - GlobeNewsWire

Avalo Reports 2022 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2022.

6 months ago - GlobeNewsWire

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present ...

7 months ago - GlobeNewsWire

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of i...

8 months ago - GlobeNewsWire

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of shar...

8 months ago - GlobeNewsWire

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK ...

9 months ago - GlobeNewsWire

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.

11 months ago - GlobeNewsWire

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future pay...

11 months ago - GlobeNewsWire

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein, AV...

1 year ago - GlobeNewsWire

Avalo to Present at the H.C. Wainwright Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present ...

1 year ago - GlobeNewsWire

Avalo Therapeutics Announces Board Changes

WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capi...

1 year ago - GlobeNewsWire

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2022.

1 year ago - GlobeNewsWire

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Topline Pivotal trial results expected 1H2023 Topline Pivotal trial results expected 1H2023

1 year ago - GlobeNewsWire